Icon

CINVANTI (nda209296)- (130MG/18ML (7.2MG/ML))

APREPITANT HERON THERAPS INC
130MG/18ML (7.2MG/ML)
Yes Yes
2035-Sep-18 Expired
None None
None No
CINVANTI is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including highdose cisplatin as a single-dose regimen. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) as a single-dose regimen. • nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen.
0 0 0
Total Other Developers 21
Drugs with Suitability No
130MG/18ML (7.2MG/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.